$ALT
Altimmune, Inc. Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000132619024000010 Filed on March 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$5.000K	$37.00K	$426.0K
YoY Change	-76.19%	-154.41%	-726.47%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.312M	$4.332M	$18.14M
YoY Change	17.24%	-74.72%	5.85%
% of Gross Profit
Research & Development	$21.49M	$16.91M	$65.80M
YoY Change	24.57%	-76.03%	-6.72%
% of Gross Profit
Depreciation & Amortization	$107.0K	$477.0K	$477.0K
YoY Change	-130.06%		-4.6%
% of Gross Profit
Operating Expenses	$26.80M	$21.24M	$83.94M
YoY Change	23.04%	-75.77%	-4.26%
Operating Profit	-$26.79M		-$95.93M
YoY Change	23.14%		9.33%
Interest Expense	$1.000K	$1.962M	$7.316M
YoY Change	-50.0%	-31.45%	91350.0%
% of Operating Profit
Other Income/Expense, Net	$2.400M	$20.00K	$166.0K
YoY Change	42.43%	-162.5%	-94.13%
Pretax Income	-$24.39M	-$31.64M	-$88.45M
YoY Change	21.52%	-62.74%	4.17%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$24.39M	-$31.64M	-$88.45M
YoY Change	21.52%	-62.65%	4.41%
Net Earnings / Revenue	-487880.0%	-85516.22%	-20762.21%
Basic Earnings Per Share	-$0.34		-$1.66
Diluted Earnings Per Share	-$0.34	-$0.54	-$1.66
COMMON SHARES
Basic Shares Outstanding	70.90M	53.73M	53.25M
Diluted Shares Outstanding	70.80M		53.25M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$182.0M	$197.8M	$197.8M
YoY Change	9.83%	7.0%	7.0%
Cash & Equivalents	$78.98M	$135.1M	$135.1M
Short-Term Investments	$103.0M	$62.70M	$62.70M
Other Short-Term Assets	$2.912M	$6.958M	$6.958M
YoY Change	-27.42%	29.04%	29.04%
Inventory
Prepaid Expenses
Receivables	$307.0K	$1.111M	$1.111M
Other Receivables	$2.272M	$3.742M	$3.742M
Total Short-Term Assets	$187.5M	$209.6M	$209.6M
YoY Change	8.32%	8.72%	8.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$544.0K	$1.014M	$1.014M
YoY Change	-45.98%	-6.2%	-39.53%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets	$299.0K	$363.0K
YoY Change	-45.24%	-40.98%
Total Long-Term Assets	$843.0K	$1.014M	$1.014M
YoY Change	-93.97%	-92.82%	-92.82%
TOTAL ASSETS
Total Short-Term Assets	$187.5M	$209.6M	$209.6M
Total Long-Term Assets	$843.0K	$1.014M	$1.014M
Total Assets	$188.4M	$210.6M	$210.6M
YoY Change	0.68%	1.79%	1.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.760M	$2.070M	$2.070M
YoY Change	-28.22%	-56.91%	-56.91%
Accrued Expenses	$7.573M	$10.07M	$10.07M
YoY Change	-22.03%	-9.1%	-9.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.33M	$12.14M	$12.14M
YoY Change	-24.2%	-28.8%	-28.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$37.00K	$4.398M	$4.398M
YoY Change	-33.93%	7230.0%	-3.99%
Total Long-Term Liabilities	$4.088M	$4.398M	$4.398M
YoY Change	-8.26%	-5.24%	-3.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.33M	$12.14M	$12.14M
Total Long-Term Liabilities	$4.088M	$4.398M	$4.398M
Total Liabilities	$15.42M	$16.54M	$16.54M
YoY Change	-20.31%	-23.55%	-23.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$490.7M	-$466.3M
YoY Change	23.31%	23.41%
Common Stock	$7.000K	$7.000K
YoY Change	40.0%	40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$172.9M	$194.1M	$194.1M
YoY Change
Total Liabilities & Shareholders Equity	$188.4M	$210.6M	$210.6M
YoY Change	0.68%	1.79%	1.79%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$24.39M	-$31.64M	-$88.45M
YoY Change	21.52%	-62.65%	4.41%
Depreciation, Depletion And Amortization	$107.0K	$477.0K	$477.0K
YoY Change	-130.06%		-4.6%
Cash From Operating Activities	-$16.36M	-$16.53M	-$75.81M
YoY Change	-15.72%	-4.48%	21.13%
INVESTING ACTIVITIES
Capital Expenditures		-$3.000K	$47.00K
YoY Change		-107.89%	-62.7%
Acquisitions
YoY Change
Other Investing Activities	-$39.52M	-$7.961M	$13.78M
YoY Change	-395.97%	-881.26%	-118.81%
Cash From Investing Activities	-$39.52M	-$7.958M	$13.73M
YoY Change	-397.11%	-911.21%	-118.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$86.93M
YoY Change			54.77%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-261.0K	72.76M	86.11M
YoY Change	-13.58%	-169297.67%	51.64%
NET CHANGE
Cash From Operating Activities	-16.36M	-16.53M	-75.81M
Cash From Investing Activities	-39.52M	-7.958M	13.73M
Cash From Financing Activities	-261.0K	72.76M	86.11M
Net Change In Cash	-56.14M	48.27M	24.03M
YoY Change	776.21%	-394.89%	-130.34%
FREE CASH FLOW
Cash From Operating Activities	-$16.36M	-$16.53M	-$75.81M
Capital Expenditures		-$3.000K	$47.00K
Free Cash Flow		-$16.53M	-$75.86M
YoY Change		-4.71%	20.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53246937
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46926349
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.altimmune.com/20231231#AccruedExpensesAndOtherCurrentLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesNoncurrent
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	0
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49199845
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70677400
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.altimmune.com/20231231#AccruedExpensesAndOtherCurrentLiabilities
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesNoncurrent
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70677400
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-32587
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALTIMMUNE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2726770
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	910 Clopper Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201S
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
CY2023	dei	City Area Code CityAreaCode	(240)
CY2023	dei	Local Phone Number LocalPhoneNumber	654-1450
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ALT
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Public Float EntityPublicFloat	184400000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70895286
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	135117000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111097000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	41000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	34000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111131000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	62698000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	73783000
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1111000
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	173000
CY2023Q4	alt	Income Taxes And Research Development Incentive Receivable Current IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent	3742000
CY2022Q4	alt	Income Taxes And Research Development Incentive Receivable Current IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent	2368000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6917000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5358000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	209626000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	192813000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	651000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1081000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	12419000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	363000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	615000
CY2023Q4	us-gaap	Assets Assets	210640000
CY2022Q4	us-gaap	Assets Assets	206928000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2070000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4804000
CY2023Q4	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	10073000
CY2022Q4	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	12250000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12143000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17054000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4398000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4581000
CY2023Q4	us-gaap	Liabilities Liabilities	16541000
CY2022Q4	us-gaap	Liabilities Liabilities	21635000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70677400
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49199845
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	665427000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	568399000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-466331000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-377884000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5004000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5227000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194099000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	185293000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	210640000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	206928000
CY2023	us-gaap	Revenues Revenues	426000
CY2022	us-gaap	Revenues Revenues	-68000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65799000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70538000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18137000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17134000
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	12419000
CY2023	us-gaap	Operating Expenses OperatingExpenses	96355000
CY2022	us-gaap	Operating Expenses OperatingExpenses	87672000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-95929000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-87740000
CY2023	us-gaap	Interest Expense InterestExpense	35000
CY2022	us-gaap	Interest Expense InterestExpense	8000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7351000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2870000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	166000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7482000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2830000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88447000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84910000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-197000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-88447000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-84713000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	223000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-187000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-88224000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-84900000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53246937
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46926349
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199135000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8101000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	950000
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-516000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	181000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56166000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6176000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-187000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-84713000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	185293000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10640000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-539000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	215000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86601000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	223000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-88447000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194099000
CY2023	us-gaap	Profit Loss ProfitLoss	-88447000
CY2022	us-gaap	Profit Loss ProfitLoss	-84713000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	86000
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	12419000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10640000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8101000
CY2023	us-gaap	Depreciation Depreciation	477000
CY2022	us-gaap	Depreciation Depreciation	493000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2471000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	698000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	154000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-34000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	938000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-256000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1345000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2650000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2734000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2770000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1883000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5393000
CY2023	alt	Increase Decrease In Income Taxes And Tax Incentive Receivable IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable	1374000
CY2022	alt	Increase Decrease In Income Taxes And Tax Incentive Receivable IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable	-3042000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75810000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62586000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	102410000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	88631000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	73273000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13732000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73399000
CY2023	alt	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	195000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	86601000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56166000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	215000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	181000
CY2023	alt	Payments Of Conditional Economic Incentive PaymentsOfConditionalEconomicIncentive	90000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	113000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	950000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	539000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	516000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86105000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56781000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24027000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-79204000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111131000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190335000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111131000
CY2022	alt	Common Stock Issued Related To Contingent Consideration Liability CommonStockIssuedRelatedToContingentConsiderationLiability	6176000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, the valuation of share-based awards, income taxes, and accruals for R&D activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates.</p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62662000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	100000
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses in these deposits.</p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	36000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62698000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	73970000
CY2022Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-187000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73783000
CY2023Q4	alt	Assets Or Liabilities Measured At Fair Value On Non Recurring Basis AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2626000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2579000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1975000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1498000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	651000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1081000
CY2022	us-gaap	Depreciation Depreciation	500000
CY2023	us-gaap	Depreciation Depreciation	500000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	500000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	500000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	671000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1124000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	363000
CY2023Q4	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	10073000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	596000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	526000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	176000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	702000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	31000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	671000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	293000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	276000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3315000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2955000
CY2023Q4	alt	Accrued Research And Development AccruedResearchAndDevelopment	5845000
CY2022Q4	alt	Accrued Research And Development AccruedResearchAndDevelopment	7295000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	496000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	452000
CY2022Q4	alt	Excess Tax Refund Payable ExcessTaxRefundPayable	1169000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	124000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	103000
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y2M12D
CY2022Q4	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	12250000
CY2023Q4	alt	Research And Development Incentive Credit ResearchAndDevelopmentIncentiveCredit	4023000
CY2022Q4	alt	Research And Development Incentive Credit ResearchAndDevelopmentIncentiveCredit	3599000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	672000
CY2023Q4	alt	Economic Conditional Incentive Grants EconomicConditionalIncentiveGrants	160000
CY2022Q4	alt	Economic Conditional Incentive Grants EconomicConditionalIncentiveGrants	250000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4398000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4581000
CY2023	alt	Research And Development Incentive Credit Earned ResearchAndDevelopmentIncentiveCreditEarned	400000
CY2022	alt	Research And Development Incentive Credit Earned ResearchAndDevelopmentIncentiveCreditEarned	3600000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70677400
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	50000
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1015166
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1015166
CY2023	alt	Number Of Warrants Exercised For Conversion Of Securities NumberOfWarrantsExercisedForConversionOfSecurities	869566
CY2023	alt	Warrants Expired WarrantsExpired	95600
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	50000
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.21
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.004
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.101
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.024
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3383937
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.20
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25724000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1760026
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.71
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24075
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.09
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	76295
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.20
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5043593
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16919000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2441054
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10063000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4757314
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	16165000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10640000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8101000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-65697000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72750000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22750000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12160000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88447000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84910000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-144000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-53000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-197000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0874
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0012
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0374
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0222
CY2022	alt	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquired In Process Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquiredInProcessResearchAndDevelopment	-0.0002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0129
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0290
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2890
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1991
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0023
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54109000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44606000
CY2023Q4	alt	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	24698000
CY2022Q4	alt	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	11996000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2787000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2193000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	757000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	523000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	357000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	540000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	182000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	309000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	56000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	110000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	107000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83056000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60274000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82958000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57245000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	98000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3029000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2847000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	98000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	164000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	18000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	98000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3029000
CY2023	alt	Testing Period TestingPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	711000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	237000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	474000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	711000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	711000
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	alt	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2023Q4	alt	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false

Files In Submission

Name	View Source	Status
0001326190-24-000010-index-headers.html	Edgar Link	pending
0001326190-24-000010-index.html	Edgar Link	pending
0001326190-24-000010.txt	Edgar Link	pending
0001326190-24-000010-xbrl.zip	Edgar Link	pending
alt-20231231.xsd	Edgar Link	pending
alt-20231231x10k.htm	Edgar Link	pending
alt-20231231x10k002.jpg	Edgar Link	pending
alt-20231231x10k004.jpg	Edgar Link	pending
alt-20231231x10k005.jpg	Edgar Link	pending
alt-20231231x10k006.jpg	Edgar Link	pending
alt-20231231x10k007.jpg	Edgar Link	pending
alt-20231231x10k008.jpg	Edgar Link	pending
alt-20231231xex21.htm	Edgar Link	pending
alt-20231231xex23d1.htm	Edgar Link	pending
alt-20231231xex31d1.htm	Edgar Link	pending
alt-20231231xex31d2.htm	Edgar Link	pending
alt-20231231xex32d1.htm	Edgar Link	pending
alt-20231231xex32d2.htm	Edgar Link	pending
alt-20231231xex4d2.htm	Edgar Link	pending
alt-20231231xex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
alt-20231231_def.xml	Edgar Link	unprocessable
alt-20231231_lab.xml	Edgar Link	unprocessable
alt-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
alt-20231231x10k_htm.xml	Edgar Link	completed
alt-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune, Inc. Stock $alt

2024 Q1 Form 10-K Financial Statement

#000132619024000010 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune, Inc. Stock $alt

2024 Q1 Form 10-K Financial Statement

#000132619024000010 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune, Inc. Stock $alt